Protocol for a multicenter prospective phase II trial of adjuvant tislelizumab combined with S-1 in subjects with residual primary lesions and node-negative esophageal squamous cell carcinoma (PPIO-008).

Authors

Ying-Jian Wang, Xv Chen, Xian-Feng Xie, Chang-Feng Li, Tao Bao, Xian-Dong He, Kun-Kun Li, Xiang-Shu Pu, Yan He, Wei Guo

Published in

Future oncology (London, England). Pages 1-10. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

http://www.clinicaltrials.gov identifier is NCT06354140 (4 March 2024). Protocol version: V2.0, dated 15 October 2026.

PMID:
42961934
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.